Skip to content
10-Q

Quarterly Report

Titan Pharmaceuticals, Inc.

0001829126-25-000026

← back to feed
Filed
Jan 3, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Dec 27, 2024 914.23K sh
Shares Diluted Q3 2024 · Sep 30, 2024 914K sh
Shares Diluted Q3 2024 · Sep 30, 2024 894K sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 751K sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 751K sh
Operating Cash Flow Q3 2024 · Sep 30, 2024 −$3.37M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$4.85M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $3.4M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $6.76M
Cash And Equivalents Q3 2024 · Sep 30, 2023 $8.1M
Stockholders Equity Q3 2024 · Sep 30, 2024 $3.23M
Stockholders Equity Q3 2024 · Jun 30, 2024 $3.99M
Stockholders Equity Q3 2024 · Mar 31, 2024 $6.09M
Stockholders Equity Q3 2024 · Dec 31, 2023 $6.64M
Stockholders Equity Q3 2024 · Sep 30, 2023 $8.13M
Stockholders Equity Q3 2024 · Jun 30, 2023 −$1.03M
Stockholders Equity Q3 2024 · Mar 31, 2023 −$312K
Stockholders Equity Q3 2024 · Dec 31, 2022 $1.36M
Current Liabilities Q3 2024 · Sep 30, 2024 $371K
Current Liabilities Q3 2024 · Dec 31, 2023 $1.44M
Total Liabilities Q3 2024 · Sep 30, 2024 $371K
Total Liabilities Q3 2024 · Dec 31, 2023 $1.44M
Current Assets Q3 2024 · Sep 30, 2024 $3.6M
Current Assets Q3 2024 · Dec 31, 2023 $8.02M
Total Assets Q3 2024 · Sep 30, 2024 $3.6M
Total Assets Q3 2024 · Dec 31, 2023 $8.09M
Eps Diluted Q3 2024 · Sep 30, 2024 −$0.83
Eps Diluted Q3 2024 · Sep 30, 2024 −$4.38
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$0.45
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$4.79
Eps Basic Q3 2024 · Sep 30, 2024 −$0.83
Eps Basic Q3 2024 · Sep 30, 2024 −$4.38
Eps Basic restated Q3 2024 · Sep 30, 2023 −$0.45
Eps Basic restated Q3 2024 · Sep 30, 2023 −$4.79
Net Income Q3 2024 · Sep 30, 2024 −$763K
Net Income Q3 2024 · Sep 30, 2024 −$3.92M
Net Income Q3 2024 · Sep 30, 2023 −$338K
Net Income Q3 2024 · Sep 30, 2023 −$3.6M
Operating Income Q3 2024 · Sep 30, 2024 −$754K
Operating Income Q3 2024 · Sep 30, 2024 −$3.89M
Operating Income Q3 2024 · Sep 30, 2023 −$2.06M
Operating Income Q3 2024 · Sep 30, 2023 −$5.35M
Rd Expense Q3 2024 · Sep 30, 2023 $424K
Rd Expense Q3 2024 · Sep 30, 2023 $1.43M